Lv6
2480 积分 2026-04-28 加入
Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study
1天前
待确认
SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial
1天前
待确认
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
2天前
已完结
Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma
3天前
已完结
Response-Adapted Surgery after Neoadjuvant Immunochemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH): A Single-Arm Phase II Trial
3天前
已关闭
Current and future therapies for triple-negative breast cancer
5天前
已完结
Preoperative Chemoimmunotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab for Previously Irradiated Recurrent HNSCC: A Prospective Phase II Trial
5天前
已完结
Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial
6天前
已完结
First-line envafolimab plus recombinant human-endostatin in advanced non-small cell lung cancer with PD-L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single-arm, phase 2 trial
6天前
已关闭
SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial
7天前
已完结
皖公网安备34019202002308
